Amicus Therapeutics (NASDAQ: FOLD) and Eli Lilly and (NYSE:LLY) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitabiliy, risk, earnings, dividends and valuation.

Institutional & Insider Ownership

75.6% of Eli Lilly and shares are owned by institutional investors. 3.4% of Amicus Therapeutics shares are owned by insiders. Comparatively, 0.2% of Eli Lilly and shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.


Eli Lilly and pays an annual dividend of $2.08 per share and has a dividend yield of 2.5%. Amicus Therapeutics does not pay a dividend. Eli Lilly and pays out 90.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Eli Lilly and has raised its dividend for 2 consecutive years.

Volatility & Risk

Amicus Therapeutics has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Amicus Therapeutics and Eli Lilly and, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amicus Therapeutics 0 0 6 0 3.00
Eli Lilly and 1 6 10 0 2.53

Amicus Therapeutics presently has a consensus target price of $13.42, indicating a potential downside of 2.07%. Eli Lilly and has a consensus target price of $88.63, indicating a potential upside of 8.29%. Given Eli Lilly and’s higher possible upside, analysts clearly believe Eli Lilly and is more favorable than Amicus Therapeutics.


This table compares Amicus Therapeutics and Eli Lilly and’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Amicus Therapeutics N/A -58.97% -20.15%
Eli Lilly and 11.12% 28.50% 10.95%

Valuation and Earnings

This table compares Amicus Therapeutics and Eli Lilly and’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Amicus Therapeutics $9.13 million 214.45 -$179.31 million ($1.53) -8.95
Eli Lilly and $21.59 billion 4.00 $5.64 billion $2.31 35.43

Eli Lilly and has higher revenue and earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.


Eli Lilly and beats Amicus Therapeutics on 11 of the 16 factors compared between the two stocks.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. Its pipeline also includes SD-101, which is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa (EB). It is also leveraging its Chaperone-Advanced Replacement Therapy (CHART) platform technologies to develop ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders (LSDs). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases, including cyclin-dependent kinase-like 5 (CDKL5) deficiency.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company’s human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company’s animal health products segment includes products for food animals and products for companion animals. As of December 31, 2016, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with's FREE daily email newsletter.